Tirzepatide Once Weekly for the Treatment of Obesity

Obesity is a chronic disease with significant global morbidity and mortality. This phase 3 double blind, randomized, controlled trial evaluated the efficacy and safety of tirzepatide, a novel glucose dependent insulinotropic polypeptide (GIP) and glucagon like peptide1 (GLP 1) receptor agonist, in 2539 adults with obesity or overweight. Participants received once weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, alongside lifestyle interventions. The primary endpoints were percentage change in weight from baseline and achieving ≥5% weight reduction. Results showed mean weight reductions of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) with tirzepatide, compared to 3.1% with placebo (P<0.001 for all comparisons). Additionally, 85–91% of tirzepatide treated participants achieved ≥5% weight loss, versus 35% with placebo. Improvements in cardiometabolic measures were observed, and adverse events were primarily gastrointestinal and mild to moderate. The study concluded that tirzepatide provides substantial and sustained weight reduction in adults with obesity.

Obesity is a chronic disease with significant global morbidity and mortality. This phase 3 double blind, randomized, controlled trial evaluated the efficacy and safety of tirzepatide, a novel glucose dependent insulinotropic polypeptide (GIP) and glucagon like peptide1 (GLP 1) receptor agonist, in 2539 adults with obesity or overweight. Participants received once weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, alongside lifestyle interventions. The primary endpoints were percentage change in weight from baseline and achieving ≥5% weight reduction. Results showed mean weight reductions of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) with tirzepatide, compared to 3.1% with placebo (P<0.001 for all comparisons). Additionally, 85–91% of tirzepatide treated participants achieved ≥5% weight loss, versus 35% with placebo. Improvements in cardiometabolic measures were observed, and adverse events were primarily gastrointestinal and mild to moderate. The study concluded that tirzepatide provides substantial and sustained weight reduction in adults with obesity.